Shi, Y., Mai, H., Chen, C., Wang, Y., Li, J., Jin, H., Peng, X., Zhang, P., Qu, S., Huang, J., He, Y., Chen, D., Pan, S., Hong, J., Zhang, N., Lei, F., Hu, D., Qing, Y., Jin, X., Ge, J. (2025). Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6004